Galaxy And Mass Assembly (GAMA): M-star-R-e relations of z=0 bulges, discs and spheroids

We perform automated bulge + disc decomposition on a sample of ~7500 galaxies from the Galaxy And Mass Assembly (GAMA) survey in the redshift range of 0.002<z<0.06 using SIGMA, a wrapper around GALFIT3. To achieve robust profile measurements we use a novel approach of repeatedly fitting the galaxies, varying the input parameters to sample a large fraction of the input parameter space. Using this method we reduce the catastrophic failure rate significantly and verify the confidence in the fit independently of \chi^2 Additionally, using the median of the final fitting values and the 16^{th}$ and 84^{th} percentile produces more realistic error estimates than those provided by GALFIT, which are known to be underestimated. We use the results of our decompositions to analyse the stellar mass - half-light radius relations of bulges, discs and spheroids. We further investigate the association of components with a parent disc or elliptical relation to provide definite z=0 disc and spheroid M-star-R-e} relations. We conclude by comparing our local disc and spheroid M-star-R-e} to simulated data from EAGLE and high redshift data from CANDELS-UDS. We show the potential of using the mass-size relation to study galaxy evolution in both cases but caution that for a fair comparison all data sets need to be processed and analysed in the same manner

Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen

Oestrogen levels play a major role in conditioning the rates of bone changes in women. Tamoxifen is a synthetic oestrogen antagonist commonly used as an adjuvant therapy for breast cancer. The goal of the present study was to study the amount and the elemental composition of bone minerals in the appedicular skeleton of women with breast cancer treated with adjuvant tamoxifen, as well as to investigate the possibility of increased risk for osteoporosis. Forty-two patients, aged 41-65 years, without skeletal metastases were studied. The mean duration of tamoxifen administration on a daily dose of 20 mg was 21 months (range 1-59 months). It was found that neither the amount of phosphorus in hands (HBP) nor forearm bone mineral content (BMC) differ statistically from those of age-matched healthy subjects. This was confirmed by reassessing bone mineral status after 30 months in 17 postmenopausal patients treated with tamoxifen for a mean time of 52 months. In conclusion, our data support that long-term tamoxifen treatment has no adverse or protective effect on the amount and elemental composition of the appedicular skeleton